Parkinsons Disease Home > Stalevo Drug Information

The U.S. Food and Drug Administration (FDA) has approved Stalevo® (carbidopa-levodopa-entacapone) for the treatment of Parkinson's disease. Specifically, this drug is approved for use in the following situations:
 
  • As a replacement for carbidopa-levodopa in people experiencing "wearing-off" symptoms (when the medication stops working before the next dose) who take 600 mg of levodopa per day or less and who are not experiencing dyskinesia, a movement disorder that is a side effect of carbidopa-levodopa.
  •  
  • As a substitute for carbidopa-levodopa (Sinemet®) tablets and entacapone (Comtan®) tablets in people already taking these medications.
  •  
The main component of Stalevo (levodopa) is used for treating symptoms of Parkinson's, while the other two components (carbidopa and entacapone) help levodopa work better and longer. Stalevo comes in the form of a tablet and is usually taken three or four times a day.
 
Although most people tolerate it well, Stalevo is not right for everyone. Safety information on this drug should be reviewed with your healthcare provider before beginning treatment. This includes knowing what products could cause drug interactions and being aware of possible side effects.
 
(For more information on this drug, click Stalevo. This article gives a complete overview, including how this product performed in clinical trials.)
 
Written by/reviewed by:
Last reviewed by: Arthur Schoenstadt, MD
Last updated/reviewed:
List of references (click here):
Other Articles in This eMedTV Presentation
Advertisement


Topics & Medications

Quicklinks

Related Channels

eMedTV Links
Copyright © 2006-2019 Clinaero, Inc.

eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.

This site complies with the HONcode standard for trustworthy health information:
verify here.